Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080437 | 0.84 | PDE3B (0.35) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL13057731 | 0.78 | ADORA2A (0.39) | PIK3CA | |
| SCHEMBL10104853 | 0.77 | PDE3B (0.40) | PDE3BPDE3AMAPK8MAPK9MAPK10 | |
| SCHEMBL18080605 | 0.77 | ALDH1A1 (0.36) | MAPTCASP3CDK9CASP7SRC | |
| SCHEMBL18080430 | 0.75 | BRD4 (0.38) | MAPT | |
| SCHEMBL18080525 | 0.75 | CASP3 (0.31) | CASP3CDK9CASP7 | |
| SCHEMBL18080606 | 0.75 | CASP3 (0.32) | CASP3CDK9CASP7 | |
| SCHEMBL18080432 | 0.74 | JAK1 (0.38) | MAPT | |
| SCHEMBL18080524 | 0.74 | KDM4E (0.34) | CASP3CDK9CASP7 | |
| SCHEMBL18080429 | 0.73 | SMN1; SMN2 (0.33) | CASP3CDK9CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | OLIPASS CORPORATION (KR) | 2022-05-03 | — | — | US | disclosed |
| US-20210292767-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2021-09-23 | — | — | US | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9085599-B2 | 2′allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-7427675-B2 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080119645-A1 | Immobilization; solid phase synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080097028-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | LSIS PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-7276599-B2 | Oligonucleotide synthesis with alternative solvents | ISIS PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070123703-A1 | CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-7169916-B2 | Chloral-free DCA in oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | PDE3B 1568/4885PDE3A 1692/4885MAPK8 2288/4885 |
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | PDE3B 556/4885PDE3A 1042/4885MAPK8 959/4885 |
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | HIF1A, HIF1AN, UPF1 | PDE3B 3673/4885PDE3A 3332/4885MAPK8 2917/4885 |
| US-20080097028-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | NEFM, NOD2, MACF1 | PDE3B 4768/4885PDE3A 4770/4885MAPK8 2050/4885 |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | PDE3B 4814/4885PDE3A 4744/4885MAPK8 3248/4885 |
| US-20080119645-A1 | Immobilization; solid phase synthesis | RNGTT, NOP2, NSUN2 | PDE3B 3378/4885PDE3A 3145/4885MAPK8 3766/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | PDE3B 4694/4885PDE3A 4456/4885MAPK8 821/4885 |
| US-20210292767-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | HIF1A, HIF1AN, UPF1 | PDE3B 3673/4885PDE3A 3332/4885MAPK8 2917/4885 |
| US-20070123703-A1 | CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS | DCLRE1B, DCTD, DDT | PDE3B 3484/4885PDE3A 3732/4885MAPK8 2795/4885 |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | PDE3B 556/4885PDE3A 1042/4885MAPK8 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.